Jarolim P, et al. - Experts attempted to study the predictive ability of changes in N-terminal B-type natriuretic peptide (NT-proBNP) concentration in patients with type 2 diabetes and ischemic heart disease who were enlisted in the Examination of Cardiovascular Outcomes with Alogliptin vs Standard of Care trial, a phase 3b trial of the dipeptidyl peptidase 4 (DPP-4) inhibitor, alogliptin. A strong graded relationship was observed between increasing baseline and 6-month NT-proBNP concentration and the incidence of major cardiovascular events. For identifying patients at highest risk for heart failure, serial monitoring of NT-proBNP in patients with type 2 diabetes and ischemic heart disease could be beneficial.